You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Ganglioside complexes as targets for antibodies in Miller Fisher syndrome
  1. H J Willison
  1. Correspondence to:
 H J Willison
 Department of Neurology, Division of Clinical Neurosciences, University of Glasgow, Southern General Hospital, Glasgow G51 4TF, Scotland; h.j.willison{at}clinmed.gla.ac.uk

https://doi.org/10.1136/jnnp.2006.094441

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The specificity of Miller Fisher syndrome sera for ganglioside complexes may influence its pathogenesis

    In the early 1990s, Kusunoki’s group1,2 showed, in two seminal papers, that antibodies directed against the ganglioside GQ1b were present in the acute-phase sera of patients with Miller Fisher syndrome (MFS). Since then, numerous studies have been published which show that anti-GQ1b antibodies and closely related anti-GT1a antibodies have a central role in MFS pathogenesis.3 In the latest paper from Kusunoki’s group by Kaida et al4(see page 1043), another fundamental issue surrounding anti-GQ1b antibodies has been uncovered, which confounds several issues and adds an intriguing layer of complexity to this highly …

    View Full Text

    Footnotes

    • Published Online First 5 June 2006

    • Competing interests: None declared.

    Linked Articles